In recent news, Edinburgh-based company Calcivis has secured £5 million in funding to bring its dental technology designed for the early detection of tooth decay to the market. The investment round was led by £4 million from the Scottish National Investment Bank and £1 million from IFS Maven Equity Finance, managed by Maven Capital Partners.
Calcivis, founded in 2012 by CEO Adam Christie and CTO Bruce Vernon, uses an imaging system that utilizes a biologic diagnostic to enable preventative treatment before tooth decay becomes irreversible. The company plans to launch its technology first in the US after receiving premarket approval from the Food and Drug Administration (FDA).
Adam Christie expressed his excitement about the potential of their technology to revolutionize prevention in oral healthcare globally, as cavities affect over two billion people worldwide according to the World Health Organization. He emphasized the importance of early diagnosis and treatment of tooth decay to prevent irreversible damage.
Paul Callaghan, investment director at the Scottish National Investment Bank, highlighted Calcivis’ role in leading innovation in health technology in Scotland. He stated that the bank is proud to support the company’s growth and help expand its product into international markets, creating job opportunities in Scotland. The bank sees Calcivis’ technology as aligned with its Innovation mission and believes that the product’s launch in the UK holds significant health benefits for the people of Scotland.
